Purple biotech convenes a head & neck cancer scientific advisory board in preparation for nt219 phase 2 trial

Nt219 recommended dose established, anti-tumor activity demonstrated rehovot, israel, feb. 13, 2024 (globe newswire) --   purple biotech ltd . ("purple biotech" or "the company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it convened a scientific advisory board (sab) focusing the discussions on nt219's indication in recurrent/metastatic squamous cell carcinoma of the head and neck (r/m scchn).
PPBT Ratings Summary
PPBT Quant Ranking